RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for RELAPSED DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowThis phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…
Matched conditions: RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo approach aims to boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving the drug epcoritamab before and after CAR-T cell therapy can help people with relapsed or refractory large B-cell lymphoma. About 31 adults will receive epcoritamab injections, then CAR-T cells, and possibly more epcoritamab if lymphoma remains. Th…
Matched conditions: RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
What happens years after CAR-T therapy? a study aims to find out
Knowledge-focused Recruiting nowThis study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…
Matched conditions: RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC